Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of MN-08 tablets in pulmonary arterial hypertension
CTR20212759Phase 2Active
- Sponsor
- Guangzhou Magpie Pharmaceutical
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nitronaphthazine in pulmonary arterial hypertension (PAH), sponsored by Guangzhou Magpie Pharmaceutical. Started Dec 2021; status: active.
02
Drugs
nitronaphthazine
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on CTR20212759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212759.